Other Events ·
Clearmind Medicine Inc. announced positive safety findings from Part A of its FDA-regulated Phase I/II clinical trial…
CMNDClearmind Medicine Inc.
Clearmind Medicine Inc. announced positive safety findings from Part A of its FDA-regulated Phase I/II clinical trial for CMND-100, a proprietary MEAI-based oral drug candidate for Alcohol Use Disorder. The study enrolled 24 healthy volunteers across four ascending-dose cohorts (approximately 20 mg to 160 mg), all of whom completed treatment per protocol with no serious adverse events observed. This consistent tolerability profile supports the compound's advancement toward subsequent clinical stages, including dosing in AUD patients. Clearmind Medicine Inc. is a clinical-stage biotechnology company developing non-hallucinogenic neuroplastogen-derived therapeutics for addiction and weight management.